Cargando…

New approaches to first-line treatment of advanced renal cell carcinoma

The treatment of patients with renal cell carcinoma (RCC) is evolving rapidly, with promising new regimens being developed and approved for patients with advanced disease, particularly the combination of tyrosine kinase inhibitors with immune checkpoint inhibitors. Within the last 6 months, favorabl...

Descripción completa

Detalles Bibliográficos
Autores principales:	George, Daniel J., Lee, Chung-Han, Heng, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435931/ https://www.ncbi.nlm.nih.gov/pubmed/34527080 http://dx.doi.org/10.1177/17588359211034708

Ejemplares similares

Individualizing Systemic Therapies in First Line Treatment and beyond for Advanced Renal Cell Carcinoma
por: Khan, Yasir, et al.
Publicado: (2020)

Optimal Management of First-Line Advanced Renal Cell Carcinoma: Focus on Pembrolizumab
por: Singh, Abhay, et al.
Publicado: (2020)

Update on first-line treatment of advanced ovarian carcinoma
por: Kemp, Z, et al.
Publicado: (2013)

Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence
por: Sun, Maxine, et al.
Publicado: (2014)

Cost-Effectiveness of Lenvatinib Plus Pembrolizumab or Everolimus as First-Line Treatment of Advanced Renal Cell Carcinoma
por: Wang, Ye, et al.
Publicado: (2022)

Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond
por: Feng, Maple Ye, et al.
Publicado: (2022)

Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review
por: Lalani, Aly-Khan A., et al.
Publicado: (2022)

New first-line treatment strategies for advanced lung squamous cell carcinoma
por: Cai, Xiuyu, et al.
Publicado: (2020)

Ipilimumab and Nivolumab as First-Line Treatment of Patients with Renal Cell Carcinoma: The Evidence to Date
por: Sheng, Iris Y, et al.
Publicado: (2020)

Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain
por: Villa, Guillermo, et al.
Publicado: (2013)

Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use
por: Lyseng-Williamson, Katherine A.
Publicado: (2018)

Contemporary Treatment of Metastatic Renal Cell Carcinoma
por: Stukalin, Igor, et al.
Publicado: (2016)

Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects
por: Moscetti, Luca, et al.
Publicado: (2020)

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
por: Rini, Brian I, et al.
Publicado: (2022)

Everolimus – a new approach in the treatment of renal cell carcinoma
por: Anandappa, G, et al.
Publicado: (2010)

Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
por: Bosma, Nicholas A., et al.
Publicado: (2022)

New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib
por: Cowey, C Lance, et al.
Publicado: (2010)

Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma
por: Bianconi, Maristella, et al.
Publicado: (2016)

Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China
por: Wang, Hao, et al.
Publicado: (2022)

First-line ICIs in renal cell carcinoma
por: Fiorentino, Vincenzo, et al.
Publicado: (2023)

Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date
por: Chau, Vincent, et al.
Publicado: (2020)

Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US
por: Watson, Tina R., et al.
Publicado: (2020)

First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?
por: Vano, Yann-Alexandre, et al.
Publicado: (2021)

Quality‐adjusted survival with first‐line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance)
por: Chen, Ronald C., et al.
Publicado: (2020)

Primary and acquired resistance to first-line therapy for clear cell renal cell carcinoma
por: Astore, Serena, et al.
Publicado: (2023)

Navigating the new landscape of second‐line treatment in advanced hepatocellular carcinoma
por: Rimassa, Lorenza, et al.
Publicado: (2020)

Optimal first‐line treatment for advanced thymic carcinoma
por: Yang, Xue, et al.
Publicado: (2019)

Clear Cell Renal Cell Carcinoma: From Biology to Treatment
por: Kase, Adam M., et al.
Publicado: (2023)

Successful apatinib treatment for advanced clear cell renal carcinoma as a first-line palliative treatment: A case report
por: Wei, Hang-Ping, et al.
Publicado: (2022)

Immunotherapy and Metastatic Renal Cell Carcinoma: A Review of New Treatment Approaches
por: Kathuria-Prakash, Nikhita, et al.
Publicado: (2021)

Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
por: Wu, Bin, et al.
Publicado: (2018)

Immune Checkpoint Inhibitor Combination Therapy versus Sunitinib as First-Line Treatment for Favorable-IMDC-Risk Advanced Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials
por: Manneh, Ray, et al.
Publicado: (2022)

Pazopanib for the Treatment of Patients with Advanced Renal Cell Carcinoma
por: Lang, Joshua M., et al.
Publicado: (2010)

Profile of temsirolimus in the treatment of advanced renal cell carcinoma
por: Staehler, Michael, et al.
Publicado: (2010)

The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment
por: Chan, Landon L., et al.
Publicado: (2023)

Efficacy of Lenvatinib and Sorafenib in the Real-World First-Line Treatment of Advanced-Stage Hepatocellular Carcinoma in a Taiwanese Population
por: Lee, Shou-Wu, et al.
Publicado: (2022)

The Combining of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Stage Hepatocellular Carcinoma
por: Lee, Shou-Wu, et al.
Publicado: (2022)

Emerging Therapies for Advanced Clear Cell Renal Cell Carcinoma
por: Toth, Alexander T., et al.
Publicado: (2020)

Phase 1b/2 trial of Ipilimumab, Nivolumab, and Ciforadenant (INC) (adenosine A2a receptor antagonist) in first-line advanced renal cell carcinoma
por: Beckermann, Kathryn, et al.
Publicado: (2023)

Safety and Efficacy of Atezolizumab and Bevacizumab Combination as a First Line Treatment of Advanced Hepatocellular Carcinoma
por: Zanuso, Valentina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6r1hc994kgmdqsploo9dm1lkfl